MISSION To eliminate needless blindness by providing evidence through research and evolving methods to translate existing evidence and knowledge into effective action.

REPORT 2009-10

1 2 INTRODUCTION

The Dr. G. Venkataswamy Eye Research Institute with its state-of-the-art infrastructural facility !"#$"%& '$O)P $$$ !+$$,/ $"""" 0$" $+1+$ +$23$/230$$ $#+"23$ ,$$$, +$ 23$&$+ $$+, 3$+ 4$"$" $ !,$$$3,$" $$ $+)$ %156%1)!7$$& "$""#4!4 $$$ &"+$,$ $)$+ $$"2+"$+ 83

3 4 CONTENTS

9&244&%#!':24)&'2 Basic Research 7 3 <= >$

9&24FF) 8

%&'29&24&2)&):)'!':2&)F'3#)#%'%'8F '$ M<

:'%N 34$ MK ' MM MH

5 6 BASIC RESEARCH

Molecular genetics of leber congenital amaurosis in South Indian population 3$ 6 3"!/!01 1 6 39>"1 6 9 ! 6 &":8/!+$0 4 6 @==L1@=?< %R/%0+ $)$ $$$'"$" $"$$"") $8, $ %$ $$%$+ &$@$$? )$$,$ $$ ?K$+ )M=P% C=P+ '$ suggests that mutations which are common in $$$&)" &%$ +%&,+ %&% +Q"3MK"):%3?"3)H" $%)$ +$ Master mix preparation for PCR ++ ++% Molecular genetic analysis of fuchs endothelial corneal dystrophy 3$ 6 3"!1 1 6 "1 SU"1 6 N# ! 6 4$) 4 6 @==H1@=?= !4$/!40""+ $4+!4$ $$)$$$+$" $ $$$$#W

7 %C??++1!4)+ %C??&!4$ $+!4?==+ 842+$$%C?? +1!R,3R +$$+$$& %C??"?MKJX)"?JHCX)$C=K8X"CL?XM

8 Genetic and functional dissection of FOXL2 gene involved in the pathogenesis of the Blepharophimosis Syndrome (BPES) 3$ 6 3"!1 1 6 :U"1 6 9&)&"3 6 S !6 & 4 6 @==L1@=?= @KN3?== + @KN3" ?@?<$&" C$FJ?Q"@?H"?HJ8" @@C\@"1 U"9222" AN 6 U ! 6 4$N"2+4 4 6 @==M1@==J A$ +)F"3")F3?")383?C< + "$ $'' %$$$+ M= $&' + + $$$ Sample preparation for sequencing reactions 9 ++842+$$ $3,1 ,+1N&4"1 63$ ! 6 %'21 4 6 @==L1@=?? U"1\" $$ 9,/9Q?0"+,$$"+ +)"> 9Q?"?==$+"?== +842+$$ 9Q?+@M$K N&:" 1 6 3"!1 U"1 6 32"+3S"U !6 4$N"2+4 4 6 @==M1@==J )$$$/KK4+"K=C" +$7JJJH@0F'"+>$ $1 )"1/)410+ ,$$)@=/,$90+$$N/$$0 4<$%)++$$$$"+$N +$N"+$1,$$

10 C-terminal deleted myocilin protein with pelB region

1/L30 %?1!+ %@1N+ %<1?=W+ %C1?$ %K1@$ %M1<$ %H1C$

1/?J@1CJM0+$N+,$4<$%+ $$)$+$$ ,$1+ 4$ Glaucoma database 3$F'" '3)2A4

11 ,""1$"$ , )>,1?/%'Q%?0$$ /)@?MK@C?Z8?=CLMM?/?C?%08

12 3#@"%'","" #"+$$$" ++FC=@#$4&! 4$$$ 4 Transcriptome and proteome analysis of ALR2 gene and its involvement in the pathogenesis of diabetic retinopathy 3$ 6 3"!1 1 6 U"1 6 8N$"2j"2& 2"# 6 88+ ! 6 4$N 4 6 @==J1@=?@ 4$/40$ ++4$ $'$%@ /0"W3$++$ )>$%@$ of DR. AL@$$+$?=@$ $$$$

13 "#?"" $N1+$%$ ?==$ 3$+$N N2&2"# %@4#/4#0 Molecular mechanism of neovascularisation in proliferative diabetic retinopathy and Eales’ disease & 6 "99"7:" N":U 6 9$$"!1 6 4"1 6 U"1 6 32$"1 6 3+ 4 6 @==J1@=?= ! 6 +$1$")&!1'4 $4$) )$\$ $/40R4/40\ )198!/W0 31?J/$$031?J ++W5&%M@C$+ N$/,":U0%& &"$4/YJ0"4 /YK0#/#0/YK0"++/&%1M"&%1L" 31?0+/98!0)+$#4 /#40+212&1 software. &$98!"W 31\/&%1M"&%1@"31?Z3[===?031?J344 +"$+/$[==KZ $[==?0$$+"+,+W /=@K501&%M/=?50"/=@?@01/!?@0 )98!"\/&%M31?0$ 344)3454 198!1&%1M

14 C D

E

$#4 ,$34CL"+$ N W+34 #4,$4CL 4 W+4 734+ W

Topical kinetics of voriconazole (1% & 0.1%) in humans 3$ 6 "!1 1 6 293>"1 %3>"1 #$"1 6 )9$"43"&& 6 $1!8/p@KN0 4 6 '/S@==JM@=?=0 9W/9j0+1$$ $+"$#+"$ W+ 1)"$+++> )>$ ? )9j @ )$$ < )=?P9j$$ &$$9j+ $+) 15 + '>?+ 4$'3" !+> ++ 4)9$"43" &&"2+4! $9j" ??J$ ++$ W$&$&& $?P=?P$9j +$&$ &&$$ + &,$"2+ j+ $9j ?P 9j+, <<<< ^51?M?35<=+ =?P+, =L?H ^51= 6 S) 4 6 )+ 6 !" %+,/)Q01 1$$&"$ 16 +$+#+"$ $+)"$ $$ + )>$ 1 )$#3%,/)Q0 \ 1 )$/=0)Q$)Q 1 ))Q$W"$ 1 )$+$)Q$ )Q #3%+$)Q \W#3%+34)$++ $)$$/$#KH062/JC6M0JC6M5+ +$$\+?5 31?L3$ /?K=QCMZ<30) )Q+ <=< &$W, $)Q $"$+ $++ :#$ after getting their written consent. 3+$)Q+ ,+ ?=P)", ?="===$?= )$+ C= < )+?==362/J6?0>#3% $+$)Q$$$+ )%'4+<=5%'7+M=5))Q+ L=1J=P Pathogenesis and molecular mechanism of age-related macular degeneration 3$ 6 9$$"!1 1 6 >"1 )>"34!+"!1 6 997R:"N":U 6 3"S ! 6 ! 11"$,+1 $$&$ 3$/30"NR/N0 $&++&&"$ +?CPM?LPC=$& @=@="L=$$+4 17 )4" $$"3"W )$++$$ /N%40/N%40$)$ 98!,$+ +$"4 $ )>$6 ? )4$ @ )$4" < )2$/&%1M"98!")2!1"34!035 4 ?CMHM/?KJ<0& ,4$+ $+41$$" "$$N$,"/HK0 +4$$"1 /!?0

AB

Drusen

1 X 4 X

C D

*

100 μm 100 μm

BM BM Sclera Choroid RPE Neural Neural Sclera Choroid RPE Retina Fig: 1 Donor eye aged 75 years showing early AMD phenotype with drusen. Photograph taken with epi-illumination !"#$&'(($( indistinct boundary, located between retinal pigment epithelium (RPE) and Bruch’s membrane (BM). Note: Mild $+$$$/69;'<=$!( normal features. RPE- Retinal Pigment Epithelium, *- Choriocapillary 18 )2,$$+35Z2+ 2"7)42+$$$$)&&&!1 "&42+>3FN81 ,8<1$$/834#01$"&1M /&%1M098+!/98!0"$$ /3?J0+)2, 35++$3?J"++ )$$31?J&%1M"98!834# +!@"@@&35$/MH0"$$ 834#"&%1M98!+$3?J/)?0! +2$35

>/69?( >H/69?( for IL-6 gene for VEGF gene

>/69?( J6;'

Table 1: Threshold Cycle (Ct) value of the genes expressed in RPE/Choroid of the donor eye & ARPE 19 cells

9 $ 834# &%1M VEGF

3?J JM @@M @C<

35/MH0 @CJ @MJ

19 Corneal surface reconstruction using cultured human limbal epithelial cells 3$ 6 8+3"!1 1 6 "1 293>"1 9$$"!1 6 )% ! 6 #$ 4 6 @==J )%4/%40$"$ +,$?@1?K1 +@1$$ ex vivo,$$+$??%4 $@==J1@=?=$+ /">05$ /$R0'@<$ ",$" $"++$H+$ Developing xenobiotic-free culture conditions to generate stem-cell rich epithelium for corneal surface reconstruction & 6 8+3"!1 9$$"!1 293>"1 :U"1 6 S")% 4 6 @==L1@=?? !N 6 %'28 $, 1+1/<)<0" /#0$$/!N0,A+ $$" $,1 A!N $<)<",$A+ ,/!0) $!+/C=KP0++$ /=JHP0!$$ 5+ &"+$/830"+ +,,$ Etiology and immunopathogenesis of presumed trematode induced uveitis 3$ 6 "1 1 6 %3>"!1 6 9)12#:""& 4 6 @==L1@=?? ! 6 %'2M!!+$ 6 %U

20 :+$ 1>++,$$+ )U/'$"@==?S'$" @==@0&" +$"1> \+@C$#$"N $$"+3+ N%)3 "$!"+, $$ $ F.gigantica F.gigantica Cercaria DNA Cercaria Environmental 100bp DNA ladder (Positive control) (Positive Negative control Negative

Subconjunctival granuloma Environmental cercaria

PCR product of environmental cercaria DNA with F.gigantica (positive control)

Cytokine profile in aqueous humor of parasitic granuloma 3$ 6 8+3"!1 1 6 "1 9$$"!1 4 6 @==L1@=?? 6 3 ! 6 %'28 8+1 $/S'$"@==@0& $"$/#0+ 1$ "#+?@1 $"?=!R$"K$"?= $#1$8 $$"$'" $+/)?0$&!R "++ #

21 +)?5)@/&%1@"&%1C"&%1M"&%1?=")2!1" &!21"0#/K$5$0\+))?&!21" +&%1M&%1?=+$ $!R/)@0! +$ :$+$ Table: 1 Profile of infiltrating cells (%mean ± SD) in the aqueous humor of Trematode-induced uveitis and Lens-induced uveitis patients Diagnosis (No. of Cases) Lymphocytes Monocytes Neutrophils Eosinophils Macrophages

)1 C?J?/@==H L/J

Table: 2 Cytokine profile in the AH of Trematode induced uveitis patients and control Diagnosis Concentration (pg/ml) – Median (Minimum, Maximum) No. of cases IL 10 IL 6 IL 4 IL 2 )1 @/="@KM0 = <K LKLH/C<"XK===0 =/?L"@H0 = /K0 /="K=K0 % @?/="JC0 =/="@@0 ?=L @@H@< @?/="@L0 =/="?C0 /K0 /@J"?JJ@0 /@@H@<"XK===0 !R = = = J</M@"?CH<0 = = heterochromic /K0 /K0 = = = ?L/?H"CH@K0 = =

Cytokine analysis using Flow Cytometer

22 Antigenic mimicry between leptospiral and human lens proteins 3$ 6 8+3"!1 1 6 "1 9$$"!1 6 3 4 6 @==L1@=?? ! 6 %'28 4$$$ $$&"+$$$5$ $#> 1$+$$in-silico ,$+$ $+@J$$$" ?L1$$$"?L$?L$$% $+$$@?M<=$$$+$$ $3& $$$$+@?4$++1$W#+"A $+$$$M%N" $in-silico+! $A%15 +1 International leptospirosis MAT proficiency testing scheme 3$ 6 8+3 1 6 6 3 $)/)0$$ $$$" )$&$$" &%$$$$& %$$)$"$>)$&" "#$"#"2%" )>/0$$ )"/0$$) $$+ %$W$$$$ $$$$$ 3"$$$$" $%$$"$ !$$@==K/C0 L!@@"@=?=)$ $$$ $$$ M5!$$

23 Molecular insights into the etiology of infectious uveitis 3$ 6 %3>"1 1 6 "1 6 S ! 6 4$N"2+4 4 6 @==L1@=?? :"+\"" $$$ &$ ??JPK=P)#$$," 9WW")$$"M. tuberculosis,$ $),$)$ ,'\ "$ 3/30$$+ )3$ $:" 3 $",$$' :"4 +:++$$$4 ,$)> : )3" $3$ ))3+M. tuberculosis,\ $$+)3 the M. tuberculosis"+)3$$) $)3+M

=H tuberculosis samples

Standard curve plot for positive control

24 Characterisation and speciation of Aspergillus and Fusarium species from corneal ulcer 3$ 6 %3>"1 6 S%3"!1 ! 6 #$ Aspergillus sp and Fusarium sp$ $ $&"3 $$&$ $+$$$$$"$+ +$$$)> $AspergillusFusarium$42+, $&)/&)$03 $"++N&

Figure 1. PCR Result of ITS region Lane 1-6: \WXY?![&[W control, M :Marker(100bp) >&\W\]^

The pathogenesis of fungal keratitis in human corneal tissue by Fusarium sp and Aspergillus sp 3$ 6 %3>"1 1 6 93>"1 U4"U>:" 3"A:"": 6 8U ! 6 %'2 4 6 @==L1@=?? >+) $$$&Fusarium sp+Aspergillus sp which C@L@P@MP$ 3 \"$$$"+$" ,,&$"$1 $$33/$

25 $0$1/30)1$/)%0+ 3R+W33$$ "$$\ cytokine genes. &"+$ ,$$)3 +3R")%1@")%1C")%1J"41?"41@"2%3<" /$$1$1$0+/&%1?"&%1?!"&%1C"&%1L" &%1?H"&%1?L"&%1@<")2!1&!21"0A $&\+ !1'+,$ 3)%1@")%1C41?"+ $1\)\ )>$$\$$ $)$)1++ $$4$$ $$ \

(a) (b)

Figure 1. Gene expression pattern of PRRs (a) and cytokines (b)

(a) (b) (c) (d) >\\_$_$ Immunohistochemistry staining of fungal infected corneal tissue section showing the presence of b) Neutrophils c) Macrophage d) CD3+T cell

26 Pathogen host interaction in human mycotic keratitis 3$ 6 293>"1 M 6 U4"U>: 6 %"1 6 "324""N ! 6 4$N"2+4 4 6 @==H1@==J >&$$ $$,'$ $$ &$", $$"$ $)+ $+$$+ &"++$$$$+ $""$$CH=P $&+$ $$++$ $3,$+,$$ +$/!?0 )$$$\+,,$ $$+)+ ,$$) )$4 &18$/4&80$/!@0

A. Flavus A. Fumigatus Green spots - Clinical Isolate 1617 ! Pink spots - ATCC Blue spots - Common to both the ATCC and CI Fig. 1 Differential expressions of the corneal protein Fig. 2. DIGE analysis of ATCC and Clinical isolate 1617 (HW$\W!$ Fusarium infected cornea

27 Proteomic profiling of serum in proliferative diabetic retinopathy & 6 9$"!1 U4"N"U: )39"1 6 92 ! 6 )&!1'4$ &$$$/C=0$" $$"$"$+ +$$ $$$4$$" $+ N$",$ >$"4+$/240"2134 $/2340"34$/340"2 )$+,$")+438 $/@4380)$+,$ 34$4$KM$"$$$ #$@1@"$34 +23434+> $""$$& $$$$"4+ +$$&$ $+,$/$0" \!$! $$"%&+$@4+ $W&

^$;9z6;/

]!\JX!&>$>'H($H( ;/'H($6;/$ 28 Identification of biomarkers for primary open angle glaucoma 3$ 6 U"1 1 6 3"!1 U41U>:" : 6 SA"&"": 6 &33+> ! 6 4$N"2+4 4 6 @==J1@=?@ 3$ 66'& /3'80 $$ +++$ $ $ )>$> $$3'8 &$+ "$"" L=$ $ )@4 $$$ $),$ 'M&<!#Y!&$!}~! 3'8$$+ Glutaraldehyde Silver, 43003vhs $+$$3'8$& $$,$+++$ $

INDEYE REVIEW MEETING &24F++!!L1J"@=?= +$$>O$&24F1 &P FROM LEFT, FIRST ROW: Dr.R.D.Ravindran, Aravind-Pondicherry, Dr.VR.Muthukkaruppan, Director-AMRF, Dr. Usha Chakravarthy, Professor, Department of , Queen’s University, Belfast, Dr. Astrid Fletcher, Professor, X$^'=‚]$!X$!;&!;JW!6! ƒW=6!6!;„$' †!6!;J![9=\!ƒ^! FROM LEFT SECOND ROW: Mr. Saravanan, AMRF, Dr. Praveen Vasisht, AIIMS, New Delhi, Dr. Liam Smeeth, Dr. Dorothea [!6!X$^'=‚]$!X$!;6^$!^^!/! Ms.Ashwini, Ms. Mohana Priya, Ms. Radha, AMRF, Dr. Badri Aravind-Pondicherry

29 PUBLICATIONS

INDIAN J BMC OPHTHALMOLOGY MOLECULAR VISION (SUBMITTED) 2009; 76(5):513-517 2010; 10:3 KATHIRVEL RENUGADEVI, ASIM GURUSWAMY NEETHIRAJAN, HEMADEVI B, SRINIVASAN M, ARUN KUMAR SIL, VIJAYALAKSHMI ABRAHAM SOLOMON, SUBBAIAH KUMAR J, PRAJNA NV, SUNDARESAN PERUMALSAMY, PERIASAMY RAMASAMY KRISHNADAS, P. SUNDARESAN PERUMALSAMY VIJAYALAKSHMI, - Genetic analysis of patients - Spectrum of candidate PERIASAMY SUNDARESAN with Fuchs endothelial genes mutation associated - Genotype/phenotype corneal dystrophy in India with Indian familial association in Indian oculocutaneous and ocular congenital aniridia HUMAN MOLECULAR GENETICS albinism patients 2010 Jan 15;19(2):287-98 MOLECULAR VISION YE M, BERRY-WYNNE KM, ASAI- CURRENT EYE RESEARCH (IN PRESS) SENTHILKUMARI S, LALITHA P, 2009;15:1781-1787 COAKWELL M, SUNDARESAN P, VENKATESH PRAJNA N, HARIPRIYA PERIASAMY SUNDARESAN, FOOTZ T, FRENCH CR, ABITBOL M, A, NIRMAL J, PANKAJ G, P.V IJAYALAKSHMI, STEWART FLEISCH VC, CORBETT N, ALLISON VELPANDIAN T. THOMPSON, AUDREY C.KO, JOHN WT, DRUMMOND G, WALTER MA, H.FINGERT, EDWIN M.STONE UNDERHILL TM, WASKIEWICZ AJ, - Single and multidose ocular kinetics of extemporaneous - Mutations that are a common LEHMANN OJ. cause of leber congenital - Mutation of the bone formulation of topical amaurosis in northern morphogenetic protein GDF3 voriconazole in human and America are rare in southern causes ocular and skeletal evaluation of its stability India anomalies PROTEOME SCIENCE (IN COMMUNICA- HUMAN GENETICS BMC (SUBMITTED) TION) ANANTHI S, SANTHOSH RS, 2009 125 (3): 340 SUGANTHALAKSHMI BALASUBBU, VENKATESH PRAJNA N, LALITHA P, RENUGADEVI K, SIL AK, SUNDARESAN PERIASAMY, ANAND DHARMALINGAM K. PERUMALSAMY V, S UNDARESAN P. RAJENDRAN, KIM RAMASAMY, NAMPERUMALSAMY PERUMALSAMY, - Development of an effective - Novel human pathological sample preparation method Mutations. Gene symbol: J.FIELDING HEJTMANCIK - Association analysis for the tear proteome analysis OCA2. Disease: albinism, using 2-D gel electrophoresis oculocutaneous II of nine candidate gene polymorphisms in Indian CORNEA patients with type 2 diabetic 2010;29:302-306 retinopathy J S MEHTA, B HEMADEVI, E N VITHANA, J ARUNKUMAR, M SRINIVASAN, N V PRAJNA, DT TAN, A TIN, P SUNDARESAN. - Absence of phenotype- genotype correlation of patients expressing mutations in the SLC4A11 gene

30 MAJOR EQUIPMENT (NEW ADDITIONS)

Vir Tis Bench Top Freeze Dryer (Lyophiliser)

&'/\^]/

]=]_J9' 31 AWARDS

DR. P. SUNDARESAN ++&A4@==J3W $ @==M82W": 1#!A"8&

MS. AMALA RAJA SUNDARI" 43$/340 O +' P@M$@==JU>:

DR. SHEETALON!3$+P )2'$/)2'0" @==J"O')M$ $+%4>P

PARTICIPATION IN CONFERENCES AND WORKSHOPS

ARVO 2009 annual meet International Society for Stem Cell 3$ !%"!"<1H Research (ISSCR) - Adult human buccal epithelial 43 N"$"SL1?? ex-vivo expansion and $$O2 VEERAPPAN MUTHUKKARUPPAN1, transplantation for corneal $ PARTHASARATHY ARPITHA1, surface reconstruction !'Q%@ SIVARAMAKRISHNAN VAISHALI1, N3$P CHIDAMBARANATHAN GOWRI 49$$ PRIYA1, USHA KIM2, VENKATESH PRAJNA2. ": "& ?Dr.G.Venkataswamy Eye +48W3" Dr. P. Sundaresan with Ms. Pamela &" ^W!\![\'XH=! 3N !" ƒ^!;\'! 83 "@#$" Professor of and Pediatrics, $ Wilmer Eye Institute, Baltimore, USA

32 ocular surface reconstruction. &$$ +: +! " : 49$$ & Dr. Gowri Priya at 6th annual meeting of International Leptospirosis Society '$": % Sixth annual meeting of International ?Dr. G. Venkataswamy Eye +4S4" Leptospirosis Society &" #" !" "$$@?1@C"@==J )$ "@9 3 48+3 "#$" $83 $+$ "<9 6 9"7 $ - Infecting leptospiral serovars :N"2 among uveitis patients - 10 49$$ &":U year study 9 3$ - Antibody dynamics in 9"7 leptospiral uveitis patients. :"N angiogenic potential of 4"4 2nd National Hands-on workshop vitreous from patients &&"2+4"!<1K" with proliferative diabetic $ @=?= retinopathy and Eales’ $ @2#1 disease by +$ Ms. P. Murugeswari who 4 has worked with Dr. Alan +$ $ Stitt, Centre for Vision and : $ Vascular Science, Queen’s +!7 $$ University, Belfast for a year : O$ as Commonwealth Fellow. 68th Annual conference of AIOS 2010 $W Biotechnology Fusion of Advanced P U"S@?1@C Research and Teaching conference 4$$ 43$ "S@1C - Glaucoma - hereditary M. VALAR NILA1, T. P. VIGNESH2, patterns based on genetic ARVO-ISOCB 2009 (International VR. MUTHUKKARUPPAN1, mutations and chromosome Society for Ocular Cell Biology) K. DHARMALINGAM3 alterations - a crash course 3"$J1?@ ?Dr. G. Venkataswamy Eye of genetics ophthalmology. P. M URUGESWARI1, R. KIM2, &" D.SHUKLA2, P.NAMPERUMALSAMY2, !" VR. MUTHUKKARUPPAN1, "@9 A.W. STITT3. "#$"

Dr. P. Sundaresan with Dr. Gerald R. Dr. S. Senthilkumari at AIIMS, Ms. P. Murugeswari, Dr.Alan Stitt at Schultz and Dr.A.J. Aldave at Kolkata New Delhi Portugal

33 [$^('=$H$ Dr. T.S. Rao, Advisor, Department of Biotechnology and Dr. Marcus Macht, "<U> K. DHARMALINGAM3. Bruker, Germany chairing the session :"3 ?Dr. G.Venkataswamy Eye $ &" Workshop on Mass Spectrometry in !" clinical proteomics in proliferative diabetic @ " 9 '+$ retinopathy. "#$" $ ANANTHI S1, VENKATESH PRAJNA < " U> $+ N2, LALITHA P2, DHARMALINGAM :"3 $<="@==J) K3 $ +$+ ?Dr. G. Venkataswamy Eye - Proteomic analysis of serum ,$ &" in patients with diabetic $ retinopathy. !" DR. MARCUS MACHT, (BRUKER, @ ANANTHI S1, VENKATESH PRAJNA " #$" GERMANY) < N2, LALITHA P2, DHARMALINGAM " U> - Comprehensive proteomics K3 :"3 analysis using ESI-QT of $ ?Dr. G. Venkataswamy Eye Mass Spectrometry &" DR. RANJAN MOGRE, (DIONEX, fungal keratitis patients !" MUMBAI) @ 5th AOHUPO Congress, 14th ADNAT " #$" - Multidimensional LC in < Convention & 1st PSI Conference " U> proteomics :"3 PROF. K. DHARMALINGAM, MADURAI on New Perspectives in Proteome $ KAMARAJ UNIVERSITY Research - Comparative analysis of - Experimental approaches to #"!@?1@K the tear and cornea protein clinical proteomics M.VALAR NILA1, T.P. VIGNESH2, VR. MUTHUKKARUPPAN1, patients.

VISITORS

)48&/&0"DR. V.M. KATOCH"+ 4$48">!?MS@==J429 3>"$ ! DR. R.B SRIVASTAVA""%N 4"%"44'#7"2+ 4DR. RP TRIPATHI"4"& 2"4 ! L@==J"+44'$> ON$$P 34 DR. RUDY A. HARTSKEERL"# %$$:")$&" ")24> "3"4$ ":# !$@L1<=4 $$ $>$$ +4"48+3" 49$$ DR. S. SWAMINATHAN"4DR. UMA MAHESWARI"3"2 N/2)N0" €N"):" )>!'<,$ $$ 2 DR. ERIC PEARLMAN"A :"!S @KO& 3P# ! U+4U4" 3N"U> :"4293>" 4%3>"" #$ PROF. TIEN-YIN WONG"4"$ &"! SJ4)1FA $+$ $>+ ! DR. MORTON F.GOLDBERG,S$8" 34 4"!4"A'$ &"S#$:": !SJ+ $>

DR. RITA BANERJEE"4$ )"3N4N>": "3N3 ": 439"!) &/!)&0" !!@@4N> +! $$$$$4$ )"2+4"&

35 MR. TOBIAS WIMMER"+" 4$'$": #$88#"8" 894$8" ! ?1@?"@=?=4)144$> $,/&180$ 4343 &$>O 8&$$P )"!+ #U@J</0,$ +$$$)+$1$342<?/^0 +42!)+ $)+$42 342<?/^0+N4) )AO,$ 98!1P 43SIXTO LEAL" A:"" '!S@C"@=?= 43$+! +$ + $ ,+ $ $+4$"! \$$ $,$O3 $P MR.CHRISTOPHER BAHL"34 4$N4 ":"! LM

GLAUCOMA SERVICES At Madurai Health literacy and other barriers to follow-up after initial diagnosis of glaucoma in south Indian population & 6 4>3 4U 6 8"1 Purpose )1$+ $+1$+$& Methods $$)1$+ #$"&) +16O$ %P/%0O)!#%P/)'!#%0 """ ""$$$" 8$"+1$ $$,?+@$R4>+ +1$@++1$$$+ )++1$, Results )"?CH>+1$+ +1$&"%+<+++ $+1$/KHLPL<+ +$++1$/6=CH?=<$"$Y==<0 $+ +1$Z%</'/'0YC=M" $Y===L0"+$/'Y?L@+$"$Y==C0 >$"++ +1$"/'Y@H@" $Y==M0 Conclusion &$$" "$&"$$ +1$!+$W+ +$+1$"+ +1$$$

37 A multi-centre, double-masked study of the safety and efficacy of Travoprost APS compared to TRAVATAN® in patients with open-angle glaucoma or ocular & 6 4>3 43 49> 42 6 8"1 Objective )$>$)$3/3 $0)9)2/NU$0"1"$ +$1$ Design 3$"$"1" Methodology $++$? @+&'3?H3+$+ into one of the treatment arms. )$3 1 '3 )9)2& 1 '3 3++$+@"+M<3$ )4"$,"&'3""#!))$ +3 4U 6 8"1 Objective )$/"&0")/3"&0 8/"&0>+$ Design 3$"$"$"$" Methodology <=>+<?6?6?$ /N90"$","&'3J6== ?@6==3$+$+>+ 3$+$>4+$ "+$"+$+ $$3 $+&'33$

38 /0"&/&0"$#" $?P&'3"$""$$$ bottle. A Multicentre, open label, active control, parallel group randomized study to demonstrate non inferiority of Brinzolamide 1% Ophthalmic suspension compared with Dorzox (Dorzolamide) 2% Ophthalmic solution in treatment of elevated intra-ocular pressure in patients with primary open angle glaucoma or ocular hypertension & 6 4U 48 Dr. Ramakrishan 6 8"1 Objective )1NW?P$$$ 4W,/W0@P$1$$ +$$$ Design ?@+$$"$"""$$" Methods @K>+@?6?)$+ $$$+1$X@C[

At Tirunelveli 1. Fluocinolone Acetonide for the treatment of diabetic 3$ 6 4 6 44%U 422 4283 ) 6 4> ! 6 "& 4 6 S@==H1$@=?= )+"+ $) !\ $ $?K$+$+?J&" "$$""$=K =@!%:'&2'%'2)'2&4> >+

39 Rinzolamide 1% ophthalmic solution for the treatment of primary open angle glaucoma and ocular hypertension 3$ 6 4 1 6 44+ 4U ! 6 %'2%/&03% 4 6 < )$&NW4W&'3$ $$/W0)$ >$)$$+ 1"$$+$NW +&$&'3 NW?=P'$$+$ +& $+"+$+$NW$ $?P$/)&40$+&'3"$ &'3/C1K#0&"$1""$M$ N&2j'%&4?P$$$+ 4'j'Q/4W0@P$$+$$ $

At Coimbatore A multicenter, open label, active control, parallel-group, randomised study to demonstrate non-inferiority of BRINZOLAMIDE 1% ophthalmic suspension compared with DORZOX (Dorzolamide) 2% ophthalmic solution in treatment of elevated intra-ocular pressure in patients with primary open angle glaucoma or ocular hypertension 3$ 6 43 1 6 489 ! 6/&03% 3 6 ?@+ Abstract 3'$8/3'80$+$ $&3'8$ "&1'3/&'30 )'$/'#0&'3$$ @?#+$NW+ &/&0$&'3 &$&&"W $"++NW$ $?P$/)&40$+&'3"$ &'3)NW++ /04W)$$$$ 1$NW)&4$+4W)&4 &'3$+3'8'#

40 At Pondicherry A multicentre, open label, active control, parallel-group randomised study to demonstrate non inferiority of brinzolamide 1% ophthalmic suspension compared to dorzox (dorzolamide) 2% ophthalmic solution in treatment of elevated intra-ocular pressure in patients with primary open angle glaucoma or ocular hypertension 3$ 6 49 1 4U ! 6 %3%" 4 6 !@==J1@=?= Objectives Primary objective )1W?P$$$W, /W0@P$1$$+ $$$ Secondary objective )W?P$$$W,/W0@P $1$$+$$ $

RETINA AND VITREOUS SERVICES At Madurai A randomised, double masked, active controlled, phase 3 studies of the efficacy, safety, and tolerability of repeated doses of intravitrial VEGF trap in subjects with neovascular Age-related Macular Degeneration (AMD) & 6 4U 4> 4: 43 6 "1 Objective 3>/&)9098!)$$ W$>+$4 Design "1"""$< Methods ?@C=>+?6?6?6?+,W?C6 =K98!)$1C+/=K7C0@98!)$1 C+/@7C0@98!)$1L+/@7L0=KW C+>/@7L0@>L++ +C>/C+0 ?>C+ /N90C)4$7%/7'%0

41 2&9!71@K'$)$/')0!$/!0 ,$$29 4">,! ?<> A safety and efficacy assessment of Vitreosolve® for ophthalmic intravitreal injection for inducing posterior vitreous Detachment in non-proliferative diabetic retinopathy subjects & 6 4U 4 6 "1 Objective )9&$> $$> Methodology <=>+2134$/2340+ + # &>=?=/?==0?L=P9&/0 # &>=?=/?==0=?=P9&/0 >>"" ?$>)+$3 +">/=0/+@+$06 ?"H"?$>)$+>+<=" M="?@=?L=$>&+$"') ,+$394

CLINICAL STUDIES Ongoing A study of featureless retina in diabetic retinopathy: Clinical and angiographic features and therapeutic implications 3$ 6 44> 1 6 44+ 6 4$ Objective )$+1 $$$ A retrospective analysis of patients with idiopathic macular telangiectasia: Natural history, incidence of visual loss and investigations of causes of visual loss 3$ 6 44> 1 6 4 4 48$ 6 4$ Objective )"&)

42 A retrospective study of the natural history of lamellar macular hole 3$ 6 44> 1 6 43 6 4 Objective )" anatomic status. A study of polypoidal choroidal vasculopathy: incidence, angiographic and tomographic features 3$ 6 44> 1 6 4: 43 6 4 Objective )$"$$$$$ $ Atypical manifestations of posterior scleritis: diagnosis and management 3$ 6 44> 1 6 44+ 6 4 Objective )$$+ $$ A restrospective study of anatomic and functional outcome of chronic macula-off rhegmatogenous retinal detachment 3$ 6 44> 1 6 44+ 6 4$ Objective )1 + A prospective study of Transpupilary Thermotherapy (TTT) for Chronic Central Serous Chorioretinopathy (CSCR) 3$ 6 44> 1 6 4)39 4 6 4 3'@==J3 Objective ))))$>, $$$1

43 Pigment Epithelial Detachment (PED) in Chronic Central Serous Retinopathy (CSCR) 3$ 6 44> ) 6 4SU"4U 6 4 Objective )')\$34R Radial optic neurotomy for ischaemic central retinal vein occlusion: a case-control study 3$ 6 44> ) 6 4>"4U 6 4 Objective )$$ +$ Brilliant blue dye for internal limiting membrane peeling in macular 3$ 6 44> ) 6 4SU 6 4 3'@==J3 Objective )$ "$ Laser photocoagulation for diabetic macular edema with serous retinal detachment 3$ 6 44> ) 6 4SU 6 4 Objective )$+ $$ Optical coherence tomography for subhyaloid haemorrhage of various etiologies 3$ 6 44> ) 6 4SU 6 4 Objective )$$ $ A study of combined occlusion of central retinal artery and vein 3$ 6 44> ) 6 4U"44+ 6 4

44 Objective )"$$ Vitrectomy for macula-threatening tractional retinal detachment in diabetic retinopathy 3$ 6 4SU ) 6 44> Objective )1 $$ Silicone oil tamponade in 23 gauge sutureless vitrectomy: long term anatomical and functional outcome 3$ 6 42N ) 6 4U 4N Objective )$$+@< 1 Yag hyaloidotomy with gas tamponade as a viable option for pre macular haemorrhage in PDR against surgical intervention by pars plana vitrectomy 3$ 6 42N ) 6 4N Objective )$$$$ 34$ IVTA Vs Macular PHC for diffuse diabetic macular edema–prospective study 3$ 6 4> 1 6 4 43 Objective )$&9)93# Isolated intravitreal for choroidal neovascular membranes of multiple aetiologies 3$ 6 4> ) 6 4N 4SU 48$ Objective )$$$W$

45 Intravitreal bevacizumab as a preoperative adjuvant for diabetic macular tractional detachments with active new vessels 3$ 6 4> ) 6 4U 44$ 44+ Objective )W$$> ++ Intravitreal bevacizumab therapy for polypoidal choroidal vasculopathy 3$ 6 4> ) 6 48$ Objective )W$3$$ Retinochoroidal coloboma - a comparison of laser barrage photocoagulation versus natural history 3$ 6 4> ) 6 4N 4) Objective )++$

AT COIMBATORE

Comparison of the safety and efficacy of fluocinolone acetonide intravitreal inserts to sham injection in subjects with diabetic macular edema 3$ 6 492/)0 1 6 49 4S ! 6 3 6 <+@@121@==M Abstract )&1==?&1==?N! /!0>+/40 +?)$>+ >$$+$$$> +?KN9/9$0@C$ )@K>,$#$W )>+""&'3"" \"$$"$5'$$ +1"" +$$

46 Investigation of efficacy and safety in wet AMD-view2 study 3$ 6 429$ 1 6 49 4S 43U/:1&0 ! 6 N3 3 6 <+?K$ /14@==M1@=??0 Abstract )/&)90$W /1$0$>+$ 4$&)9 >+$4$@>+ C+/N90C) 4$/)40$7%/7'%0+2& 9!71@K'$)$/')0!$/!0 ,+$)$&)9 1/7'%0>+$4" 2&9!71@K+'@==>&/'?@C=>0 #$?H$J=P3 /30 A multicenter, open study assessing the efficacy and safety of (intravitreal injections) as adjunctive therapy to laser in patients with visual impairment due to Diabetic Macular Edema(DME) 3$6 429$ 16 4 4S ! 6 2 3 6 ?+1@==J Abstract )W+$+ 4)$> 3$+<>+ $>$>$+ +$9"N9/N90" ')/'$)$0W'?J $ A 12 month randomised pilot study to compare the efficacy and safety of PDT (standard Fluence) plus intravitreal Lucentis vs. PDT (reduced Fluence plus intravitreal Lucentis) 3$6 429$ 16 4 4S ! 6 2 3 6 ?/1@==H1@==J0

47 Abstract )?+?=1?@'$" M=3)+$+>+?< /?<9+N"??@0)+W +$934)+%+ 9+9+

AT PONDICHERRY Fame study A randomised, parallel group, multicentre, dose finding, comparison of the safety and efficacy of ASI-001A 0.5G/Day And ASI-001B 0.2 G/Day Fluocinolone Acetonide Intravitreal Inserts To Sham Injections In Subjects With Diabetic Macular Edema 3$ 6 44 1 6 4) 43>4 4 6 2@==M1$@=?= ! 6 &'$3%" Primary Objectives )$>+>$ $+$$$>+?K N9/9$0?L ? $\" @ $@$$" < &1==?&1==?N4$

VITREOSOLVE : A phase 3 safety and efficacy study of Vitreosolve® for ophthalmic intravitreal injection for inducing posterior vitreous detachment in Retinopathy subjects 3$ 6 44 1 6 4) $ 6 9)"& 4 6 @==L1@==J Objective )>9&'$ >$

48 VEGF trap–eye: investigation of efficacy and safety in wet AMD """$<"" $98!)$1>1 4/40 3$ 6 43>4 1 6 4) $ 6 N#"N3 6 @==LM@=?? Primary objective )/&)9098!)$1$W /1$0$>+$ 4 Secondary objectives )$&)998!)$1>+ $4$@ )$&)998!)$11 /7'%0>+$4"2&9!71@K ),$

ORBIT AND OCULOPLASTY SERVICES AT MADURAI National retinoblastoma registry & 6 4:U 1 6 4U ! 6 &/&0 4 6

49 Randomised, double blind, active controlled study of the efficacy, surgical outcome and complications of Silicone Rod Sling in frontalis sling suspension surgery 3$ 6 4:U 1 6 4U$ Objective )$"$ $ Methodology 3,+ !$+ 3++$"3$ $)+ Socket reconstruction using Bio-engineered autologous oral mucosal epithelium 3$ 6 4:U 4U$ 1 6 48+3 49$$ 3 6 S@==H1@==J )+$$1 "$" $$$& "$$$&+," $$$$+ ">")" )>$$$$+W ,,$$ Oral Clonidine premedication in patients undergoing dacryocystorhinostomy under local anaesthesia & 6 4 4:U 43 6 '"#$" Objective )$> $$, 3$"4"3"/)0K=> ,$+ $?K=J=1?@= N$+ 3/1$$$0+?1?== 3$"$+ $$

50 Prospective clinical evaluation of Dacryocystorhinostomy (DCR) with lacrimal intubation & 6 4:U 43 4U3 6 '"#$" Objective: )2 % Design 3$"<=>+& ++>4+$$" ",","$$4+ $+\$+ ,+1$+) +<"+ $+)$$+ +$$$ $3++$" ",++<=$

CORNEA SERVICES AT MADURAI

AURO KPRO 6 4S +$M$ )$ Mycotic Ulcer Treatment Trial (MUTT) 3$& 6 4293> 3> 6 4)% $ 6 2& 6 #$/"30 Study Objectives )>:))+$"9W 2"$ )+1+$ )$$ )," Steroids for corneal ulcer trial )+$2&#"$

51 SICCA study 3$ 6 4 ! 6 2&# )$$&$$

AT TIRUNELVELI

Steroids for Corneal Ulcer Trial 3$ 6 4 1 6 4 44%> ! 6 3!": 3 6 $@==M1!@=?= )$$"1"$1+ $$$ !$#$ /")"0"41#3 !":"!+$ $$)$+$1 N"$$ $$"+" $ )> # )+$$ $1 # )+$ outcomes # )+$ )$+$M "$1 )"1"$1+ $$$ )+3/:!0)+ $R=M))+<+,$!@=?=A ?KM$)"@

AT PONDICHERRY

Mycotic Ulcer Treatment Trial (MUTT) & 6 4)U 42 Specific aims ? )+$1"W" acuity. @ )+"W" $ 52 < )++$ in fungal keratitis. C )+$$/'$ 0 Study design )$$,"1"+" W" corneal ulcers.

CATARACT AND IOL SERVICES AT MADURAI

Posterior capsular opacification after implantation of square edge PMMA, Round edge PMMA and hydrophobic acrylic intraocular lenses: A prospective, randomised comparative trial & 6 4#$ 4 4 6 "#$" Objective )$$$$/3'0+3"3 $11$ $$"")/)0)+ K=$33+ &$"K=$3$ +3+$,""" $$'3')3'$ $,"$$+3'+ 3'+JC$+J<++$ "LJ>++$LC++$! +1$+@=?= Clinical evaluation of hydrophobic foldable IOLs & 6 4#$ 4 42>+ 6 "#$" Objective )#$!&%/0 "$$"$)&N$$ $+&'"83!4+++ 3+$+$W@=+$ $3+$?"@"<"H"?K""", $$$W?@=>) 3'$$,"$$+ 3'+W3'++@J"@==H) $+?L3+$?"?="C="?@=" $$+"?=J$$+$

53 N$)+$ is ongoing. Capsule wash for paediatric eyes & 6 4#$ 439> 4$)/&":0 6 "#$" Objective )>++%&$+$ $$/3'0$)+$$Z /)0)! $W+@@?=P+$!$W+M9 $+M?K+3 +$$+ >$!"$++ '$/8$?0+++%& $/8$@0+++%&>++$ "","+"+M$4+ $$+++ To analyse the effect of CTR on Anterior Capsular Opening (ACO) in eyes with retinitis pigmentosa & 6 44 4#$ 6 "#$" Objective ))$'$/'0+3 $$Z/)03+ +))$3+ $&'%+C=$)+$+) 3++$"","+$$'+ 3'+ ,$++ '/P0 , Y 11111111111111111111111111111 Q?== $ N'/P0 /?3$0 )+)' 3$"+$+ )$ Hemodynamic response to routine phacoemulsification among normal healthy ophthalmic surgeons during high volume cataract surgery & 6 43"4#$ 6 "#$" Objective )$$$/30 $$

54 Methods !"3",$+ $" $/N30/#0+ $$$3) $3+6+"$,"3$$ /^0"1$&'%$)#$ $N3+ Results )+$+$< N3$$2'9 +$"",$ +N3)+++# +$ Comparison of phacoemulsification vs. SICS: A randomised control trial & 6 4#$"4) 6 "#$" '>$3/30+ /&0$+$+ ,"$$"" ?C=$+W?6?!3$"$+ $&"<$$+ $$/2M'A!0&'%!&$" +$/H0+ $$3/jM'N40&'%"N"$ /'940"$$+3 +$+""",+$$3$ "$,"&'3" "/7'%0 1?C+?=<>$,+$ Role of wetlab training in donor eyes and simulator for learning capsulorhexis & 6 4#$ 42> 434 4)33 6 #$" Objective )$F$, surgeons Method &$$++,$+ ++$$8$1? ++$,$1@$ ?K)++$,& $

55 ) 1 \$ 1 - Time 1 )$ 1 $, +?$+= '$" +$+"H ongoing. Cataract and its treatment – patient awareness and public myths & 6 43 4#$ #S4 4 Aim )$+M Methods @M$+,$$"+ $++/@@L?P0Z+$$ /?@KP0"/KM/@HP0 R,$)+ +/MLMLL=P0+$ $++/@C@LP0$+ /C?@LP0"+/CHH

56 Methods &$?CL?CL$$+&'%$ +S@==H4@==L3+<$1$?1 3&'%/YM=0"$@1&!&'%/YMH0"$1<!&'%/Y@?04 $"&'%$+&'%+ $+$3++$ ?",

UVEA SERVICES AT MADURAI

A double – masked, Placebo-controlled, multicentric, parallel group, dose ranging study to assess the efficacy and safety of LX211 as therapy in subjects with non-infectious intermediate, anterior and intermediate, posterior or pan-uveitis 3$ 6 4"1 4NN"1 1 6 492"1 4 6 ?LM?@"M+$ Objective %Q@??$$$$+$ +$)>+ %Q@??>+ %Q@??1=? 6 )" "$$1 %Q@??1=@ 6 )"1" "$$ %Q@??1=< 6 ) Protocol: CAIN457C 2303 : A 24 week multicenter, randomised, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs. placebo adjunctive to standard-of-care immunosuppressive therapy 3$ 6 4"1 1 6 4N"1 4 6 M Objectives )&2CKH>11$$$ $>11$$$ ,NR Protocol CAIN457C2301: A 24 week multicenter, randomised, double-masked, placebo controlled, dose -ranging phase 3 study of AIN 457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression in patients with quiescent ,non-infectious intermediate, posterior or panuveitis (ENDURE study) 3$ 6 4"1 4NN"1 1 6 4N"1 42"1

57 ! 6 2'9)& 4 6 M Objectives )&2CKH$$$$ \$"$$ ++$$$+" 1"$

PAEDIATRIC OPHTHALMOLOGY SERVICES AT MADURAI

A2Z Child blindness and eye health project 3>, 6 439> ! 6 4$ 4 6 ?'@==L

Effect of square edge PMMA IOL in preventing lens epithelial cell migration in paediatric cataract surgery: A randomized controlled trial & 6 439>"4 6 3"#$" Objective )$$$$/3'0+3 $"W) 3$+K?=+$$ $W<=$$+"@==M ?J$+!+$$<="?L="$+$+$

PUBLICATIONS

ARTICLES PUBLISHED IN PEER REVIEWED JOURNALS

International Journals OPHTHALMIC SURG LASERS IMAG- 2010 Mar 9:1-3. (Epub ahead of ING print) SHUKLA, DHANANJAY; DHAWAN A. BR J OPHTHALMOL VOL: 40 (2) 2009 (Mar-Apr) - Evolution and management of a VOL: 93 (4) 2009 APR. P.429- P.115-119 post-uveitis macular hole 434 SHUKLA, DHANANJAY; BEHERA, NAMPERUMALSAMY, P; KIM, R; UMESH CHANDRA; CHAKRABORTY, 2010 Mar 1-7 (Epub ahead of print) VIGNESH, T P; NITHYA, N; ROYES, SOMNATH; MAHALAKSHMI, SHUKLA, DHANANJAY; RAMCHANDANI, J; GIJO, T; THULASIRAJ, R D; RAJENDRAN; PRASAD, NOELA MARIE B; VIGNESH, TP; ANAND, RAJENDRAN; VIJAYAKUMAR, V - Serous macular detachment NEELAKANTAN, NITHYA - Prevalence and risk factors for as a predictor of resolution of diabetic retinopathy: a population- macular edema with intravitreal - Localized serous retinal detachment based assessment from Theni triamcinolone injection of macula as a marker of malignant hypertension district, South India VOL: 40 (5) 2009 SEP.-OCT. VOL: 93 (5) 2009 MAY P.701- P.501-503 2010 Mar 9:1-3. (Epub ahead of print) 702 SHUKLA, DHANANJAY; KANUNGO, SENGUPTA, S; VENKATESH, R; ROE, R H; RATHINAM, S R; WONG, SANGHAMITRA RAVINDRAN, R D R W; MCDONALD, H R; JUMPER, J - Surgical repair of iatrogenic M; CUNNINGHAM J., E T macular hole secondary to - Unilateral optic nerve entrance - Delayed fellow eye involvement vitrectomy for long-standing coloboma: The broken disc anomaly in patients with vogtt-koyanagi- traumatic retinal detachment harada disease

59 CURR OPINION OPHTHALMOL VOL: 23 (5) 2009 MAY P.1155- HUM GENET VOL: 20 (4) 2009 JUL. P.318-323 1157 2009 (Apr) 125 (3) P.340. VENKATESH, R; TAN, C S LALITHA, PRAJNA RENUGADEVI, K; SIL AK; H; SINGH, G P; VEENA, K; - Nocardia keratitis VIJAYALAKSHMI, P; SUNDARESAN, P TIRUVENGADAKRISHNAN, K; - Novel human pathological RAVINDRAN, R D OPHTHALMIC EPIDEMIOLOGY #$%&'# VOL: 16 (3) 2009 JUN. P.193-197 Disease: albinism, oculocutaneous KATZ, JOANNE; TIELSCH, JAMES small incision cataract surgery for II. M; THULASIRAJ, RAVILLA D; brunescent and black cataracts COLES, CHRISTIAN; SHEELADEVI, 2009 AUG. P.1-2 CORNEA SHEELA; YANIK, ELIZABETH L; ANAND, RAJENDRAN; GUPTA, S R; VOL: 28 (3) 2009 APR. P.317- RAHMATHULLAH, LAKSHMI BRAHADEESH, S; KIM, R 320 - Risk factors for maternal night - Intravitreal bevacizumab for REVATHI, RAJARAMAN; SINGH, blindness in rural south India choroidal SATINDERPAL; ANITA, RAGHAVAN; associated with a retinochoroidal KARKHANIS, AMAR OPHTHALMIC PLAST RECONSTRUC- coloboma ( TIVE SURGERY ]*+/2 COMMUNITY EYE HEALTH VOL: 25 (5) 2009 SEP.-OCT. tamponade and compression sutures Vol: 22(70) JUN. 2009 p.S2 USHA, KIM R; VIPUL, ARORA; for the management of acute corneal SRINIVASAN, V SHANTI, R; AKASH, D SHAH hydrops - Neglected giant atypical - Equipment repaired is equipment Vol: 28 (8) Sep. 2009 P.951-954 gained LA´SZLO´ KREDICS; JA´NOS VARGA; 2010 Jan-Feb; 26(1):30-2. VOL: 22 (71) DEC. 2009 p.39-41 SA´NDOR KOCSUBE; REVATHI, UPADHYAY, MADAN P; SRINIVASAN, RAJARAMAN; ANITA, RAGHAVAN; USHA, KIM R; VIPUL, ARORA; M; WHITCHER, JOHN P ILONA DO´CZI; MADHAVAN BHASKAR; RAMCHANDRAN, S; AKASH, D SHAH; TIBOR MIHA´LY NE´METHM; PHELPS, PO - Managing corneal disease: focus on ZSUZSANNA ANTAL; NARENDRAN, - Orbital hyalinizing spindle cell suppurative keratitis V; C VA´GVO¨LGYI; ROBERT A. tumor with giant rosettes SABA CLINICAL RHINOLOGY SAMSON; MANOHARAN CHOCKAIYA; Mar.- Apr. 2010 SEP.-DEC. 2009 P.47-50. AND MANIKANDAN, P USHA, KIM R; SHAH, AKASH D; RAJINIGANTH, MG; USHA, KIM R; SHANTI, RAMACHANDRAN; ARORA, - Infectious keratitis caused by MAHESH KUMAR VIPUL aspergillus tubingensis 2010 Jan 28. [Epub ] - Primary adenoid cystic carcinoma isolated acute sphenoid sinusitis MEHTA, JS; HEMADEVI, B; VITHANA, of the eyelid EN; ARUNKUMAR, J; SRINIVASAN, M; MOL VISION ARCH OPHTHALMOL. PRAJNA, NV; TAN, DT; AUNG, T; VOL: 15 2009 (Sep. 4) P.1781- SUNDARESAN, P 2010 VOL: 128(1) Jan. P.28-32. 1787 BALASUNDARAM, MB; ANDAVAR, R; - Absence of phenotype-genotype SUNDARESAN, P; VIJAYALAKSHMI, P; MANIKANDAN, P; NARENDRAN, V THOMPSON, STEWART; KO, AUDREY 3'44 - Outbreak of acquired ocular C; FINGERT, JOHN H; STONE, EDWIN M JR CLINICAL MICROBIOLOGY patients - Mutations that are a common VOL: 47 (10) 2009 OCT. EYE cause of leber congenital amaurosis P.3382-3385 in northern America are rare in MANIKANDAN, P; VARGA, JANOS; VOL: 23 (4) 2009 APR. P.945-956 southern India KOCSUBE, SANDOR; SAMSON, ROBERT RAMAKRISHAN, R; JAYAHAR, M 2010 Mar 5;16:353-8 A; ANITA, RAGHAVAN; REVATHI, BHARATHI; SHIVKUMAR, C; MITTAL, TIERCY JM; RATHINAM, SR; GEX- R; DOCZI, ILONA; NEMETH, TIBOR S; MEENAKSHI, R; KHADEER, M A; FABRY M; BAGLIVO E MIHALY; NARENDRAN, V; VAGVOLGYI, AVASTHI, A - A shared HLA-DRB1 epitope in the CSABA; MANOHARAN, CHOCKAIYA; !" KREDICS, LASZLO with Vogt-Koyanagi-Harada endogenous endophthalmitis: a - Mycotic keratitis due to aspergillus syndrome in Indian patients. 10-year retrospective study nomius

60 VOL: 47 (5) 2009 MAY P.1463- J NEURO OPHTHALMOLOGY GLOB 1468 VOL: 29 (6) 2009 JUN. P.154 2010 Feb AZOR, MONICA; GENE, JOSEPA; CANO, SENGUPTA, SABYASACHI; DHANAPAL, LEWALLEN, S; THULASIRAJ, RD JOSEP; MANIKANDAN, P; NARENDRAN, PRAVEEN; RAVINDRAN, R D; NIRMALA - Eliminating cataract blindness - V; GUARRO, JOSEP DEVI How do we apply lessons from Asia - Less-frequent fusarium species of - Cerebral blindness after scorpion to sub-Saharan Africa? clinical interest: correlation between sting morphological and molecular BMC OPHTHALMOLOGY POSTGRAD MED J. February 2010 susceptibility Vol: 85(1010) DEC. 2009 HEMADEVI, BOOMIRAJ; SRINIVASAN, p.643-8 J AAPOS M; ARUN KUMAR, J; PRAJNA, NV; NAMPERUMALSAMY, P; KIM, R; SUNDARESAN, P VOL: 13 (5) 2009 OCT. P.485-487 VIGNESH, TP; NITHYA, N; ROYES - Genetic analysis of patients with AJAY YELIATHAYA HARISH; SANDRA, C J; GIJO, T; THULASIRAJ, RD; fuchs endothelial corneal dystrophy GANESH; KALPANA, NARENDRAN VIJAYAKUMAR, V in India - Traumatic superior oblique tendon - Prevalence and risk factors for rupture diabetic retinopathy: a population- HUM MOL GENET. J PEDIATR OPHTHALMOL STRABISMUS based assessment from Theni 2010 Jan 15;19(2):287-98 district, south India YE M; BERRY-WYNNE KM; ASAI- 2009 Jun 25 P.1-2 COAKWELL M; SUNDARESAN, P; PARAG, K SHAH; NARENDRAN,V; IOVS FOOTZ T; FRENCH CR; ABITBOL M; KALPANA, NARENDRAN VOL: 51 (2) Feb. P.701-707. FLEISCH VC; CORBETT N; ALLISON - Appearance and spontaneous TIRUVENGADAKRISHNAN, K; WT; DRUMMOND G; WALTER MA; resolution of macular pucker after RAVINDRAN, R D; MURTHY, UNDERHILL TM; WASKIEWICZ AJ; triple freeze-thaw cryotherapy for GUDLAVALLETI VS; PRAVEEN, LEHMANN OJ retinoblastoma VASHIST; KATHRYN E. FITZPATRICK; - Mutation of the bone morphogenetic THULASIRAJ, RD; NEENA JOHN; J CATARACT REFRACT SURG $!/+ GIOVANNI MARAINI; MONICA skeletal anomalies VOL: 35 (4) 2009 APR. P.629-636 CAMPARINI; USHA CHAKRAVARTHY; RAVINDRAN, R D; VENKATESH, ASTRID E. FLETCHER National Journals R; CHANG, DAVID F; SENGUPTA, - Prevalence of early and late age- S ; GYATTSHO, JAMYANG; ABYASACHI related macular degeneration in TALWAR, BADRINATH INDIAN J OPHTHALMOL India: the INDEYE study - Incidence of post-cataract VOL: 57 (5) 2009 SEP. P.385-386 endophthalmitis at Aravind Eye RETINA VIPUL, ARORA; USHA, KIM R; KHAZEI, HADI M; KUSAGUR, Hospital: outcomes of more than 2010 Feb 17. Epub . SHIVAYOGI 555 MARTIN, TD; RATHINAM, SR; standardised sterilisation and CUNNINGHAM, ET JR - Ophthalmic complications including retinal detachment in - Prevalence, clinical characteristics, (*6S2 and causes of vision loss in children INT OPHTHALMOL (EPUB AHEAD OF PRINT) Syndrome: case report and review of with Vogt-Koyanagi-Harada 2009 Aug 27 literature disease in south India KHAIRALLAH, M; CHEE, SP; VOL: 57 (5) 2009 SEP. P.387-389 RATHINAM, SR; ATTIA, S; NADELLA, V OPHTHALMOLOGY VIPUL, ARORA; USHA, KIM R; - Novel infectious agents causing 2010 Feb;117(2):253-8. [Epub KHAZEI, HADI M uveitis 2009 Dec 6.] - Delleman oorthuys syndrome: 2010 Feb 3. HENDERSON, BA; KIM, JY; GOLNIK, Oculocerebrocutaneous syndrome MURALIDHAR, R; VIJAYALAKSHMI, P; KC; OETTING, TA; LEE, AG; VOLPE, VOL: 57 (5) 2009 SEP. P.395-398 GUNDA, AK NJ; AARON, M; UHLER, TA; ARNOLD, USHA, KIM R - Inferior rectus paresis and medial A; DUNN, JP; PRAJNA, NV; LANE, - Multimodality treatment rectus overaction following AM; LOEWENSTEIN, JI approach in management of retrobulbar anesthesia for cataract - Evaluation of the virtual mentor primary peripheral primitive surgery. cataract training program neuroectodermal tumor of the orbit

61 VOL: 57(5) SEP. 2009 P.398-400 VOL: 58(2) 2010 Mar-Apr. OPHTHALMIC SURG LASERS IMAGING P.151-2 VISHWAKARMA, P; GANESH, V Mar 9 2010; 1-7. doi:10.3928/ RAMAN; SATHYAN, P MANAYATH, GJ; PARAG, K SHAH; 15428877-20100215-74 NARENDRAN, V; MORRIS, RJ - Mefenamic acid-induced bilateral SHUKLA D, RAMCHANDANI B, transientmyopia, secondary angle - Idiopathic pediatric retinal artery VIGNESH TP, RAJENDRAN A, closure glaucoma and choroidal occlusion NEELAKANTAN N. detachment. HIGHLIGHTS OF OPHTHALMOLOGY - Localised serious retinal detachment of macula as INDIAN J RADIOL IMAGING AUG. 2009 a marker of malignant KARAN KUMAR; KRISHNADAS, R VOL: 19(4) 2009 NOV. P.298-300 hypertension USHA, KIM R; VIPUL ARORA; AKASH - Update on medical treatment of 2009 p.115-119 D SHAH; SRINIVASAN, K G congenital glaucomas SHUKLA, DHANANJAY BEHERA, - Ocular malformation with a double INDIAN J MED RES UMESH CHANDRA; CHAKRABORTY, globe appearance SOMNATH; MAHALAKSHMI, VOL: 130 DEC. 2009 P.749-757 RAJENDRAN; PRASAD, NOELA MARIE INDIAN JOURNAL OF PEDIATRICS JAYAHAR, M BHARATHI; - Serous macular detachment VOL: 76 (8) AUG. 2009 P.801-804 RAMAKRISHNAN, R; MEENAKSHI, R; as a predictor of resolution PARAG, K SHAH; NARENDRAN, V; SHIVAKUMAR, C; LIONAL RAJ, D of macular edema with KALPANA, NARENDRAN; CLARE - Analysis of the risk factors intravitreal triamcinolone GILBERT predisposing to fungal, bacterial and injection - Severe retinopathy of prematurity acanthamoeba keratitis in south Mar 9 2010; 1-3 (Epub ahead of India in big babies in India: History Print) repeating itself SHUKLA D, DHAWAN A VOL: 76 (5) 2009 MAY P.513-517 CAN J OPH DR. DHANANJAY SHUKLA, - Evolution and management of NEETHIRAJAN, GURUSWAMY; DR. UMESH BEHERA, DR. a post-uveitis macular hole SOLOMON, ABRAHAM; KRISHNADAS, S S.R.RATHINAM, DR. EMMETT R; VIJAYALAKSHMI, P; SUNDARESAN, P T.CUNNINGHAM, DR. ANURADHA INTERNATIONAL OPHTHALMOLOGY - Genotype, phenotype association in DHAWAN CLINICS Indian congenital aniridia - Atypical acute posterior 50(2): 113-124, Spring 2010 VOL: 58 (1) 2010 Jan-Feb P.21-7. multifocal placoid pigment SHUKLA, DHANANJAY; RATHINAM, MANOHAR BABU, B; RATHINAM, SR epitheliopathy associated with SIVAKUMAR R.; CUNNINGHAM, - Intermediate uveitis serous retinal detachment: EMMETT T. JR VOL: 58 (2) 2010 Mar-Apr. Clinical and angiographic - Leptospiral uveitis in the P.153-5 features and treatment developing world PRATEEK, AGARWAL; MAHESH KUMAR; VIPUL, ARORA OSLI January 2008; 39(81-85) sinus thrombosis and the role DR. DHANANJAY SHUKLA, DR. of imaging in its diagnosis in ANAND RAJENDRAN, DR. SOMNATH patients with presumed idiopathic CHAKRABORTY intracranial hypertension - Vitrectomy for macular hole associated with rhegmatogenous retinal detachment

62 OPERATIONS RESEARCH

Comparison of Uptake of spectacles for refractive error across different delivery systems – A cluster randomised controlled trial 3$ 6 4) 1 6 S$ 4)> 99> 9 S&> Introduction $ $1$$#$R$, $"$$11$ )$$) $$$ Objectives # )$$$ # )$$ # )$$ Current Status: $8$ Gender analysis of Cataract Surgical Services in South India 3$ 6 S$ 1 6 4)> S&> &$$$ ++) +,$1$$1" +?JL=@===Z++$@==? +$$,+$$++"+ "$+$)81 $ #$+1 Current Status $8$

63 Human resource practices which influence employee satisfaction and patient satisfaction & 6 4)> , 6 49"3#4$"# "&&) 4)SU"3"4$"&&) 6 33"%&'

Introduction ,+$$ )"$+ $\$$) +$) ,$$"$ $+$$$&) $++$ Objectives of the study 1)$$ 1)$$$ $, 1)$$"$$$$ +$$ 1)++$$$$$ $ Current status $)+S@=?=

64 PRODUCT DEVELOPMENT

Aurovue new metal injector S@=?= R&'%> #$M)+$ +$ ) $$ Aurolac S@=?= R"% &)$$$4 44$ +++ $ ,$€ $ € )$$ $$ Nanocut S@=?= RNO2P$ ) Aurosil plus @==J R$O3P 'K===@5/0)$ $$ $+ Eye drops R$ +$ O)'N14QP)=

65 ORGANISATION

Aravind Medical Research Institutional Review Board Research Advisory Foundation (AMRF) Board (IRB) Committee (RAC)

3 DR. P. NAMPERUMALSAMY DR.P. NAMPERUMALSAMY, MS, FAMS DR. K. DHARMALINGAM " 93 3€# DR.G. NATCHIAR, MS, DO N ?"2"1@= U>: DR. VR. MUTHUKKARUPPAN €) 1@? Director - Research DR.R.KIM, DO, DNB Director-Research DR. SR. RATHINAM ! 4$&€ 3'$ ?"2"1@= N #: DR. A. GNANAM DR.VR.MUTHUKKARUPPAN, M.SC., #$" !9 PH.D N"€ 4$8 MR. M. MARIAPPAN 3: 1@"U$ DR.P.SUNDARESAN, M.SC., PH.D 32: DR. T.S. CHANDRASEKARAN M@? 4$' '$ 3 ?"W2"82 DR. A. AYYAPPAN 1@= 3€#"4$ € DR. S. SENTHILKUMARI, M.PHARM., DR. C. SRINIVASAN 8>>#$ PH.D :83 1M@K=@= 34!+ 4$ DR.T.AMALA RAJA SUNDARI, M.SC., MR. G. SRINIVASAN PH.D U>: 4M! 34!+ 1@? MS. B. SUGANTHA LAKSHMI, M.SC ?"2"M@= DR. L. THAYUMANAVAN 8 DR. N. VENKATESH PRAJNA 9#$ M4$ J"9"" 1M@K=@? ?"2"M@=

DR. LALITHA PRAJNA DR. S.P. THYAGARAJAN 1 4M 2?"2 2K&"22 MM@K=@= "MM===@= DR. SR. KRISHNADAS ' ?"2"M@= 66 RESEARCH SCHOLARS AT AMRF

Scholar’s Name Guide 3> )> 49$$ N 34!+ 4> $$ N 43 34!+ 4U mutation screening for congenital cataract 3+ 49$$ 3 S!1%'2 4U $ 44 4293> 3 JRF-DBT 4U4 mycotic keratitis N# 43 8!R S!14) 4SU 4$/!40 # 4 4$/#40&$ S 48+3 $ S!1%'2 4293> cells 49$$ U 43 & JRF-DBT 439> &'/'0 '/'0 + 43 8$&24F )1&24F 44 & )% 48+3 ,,$$ )1# 4293> $ 49$$ % 4 &$ S!1%'2 4%3> : 9 43 % S!1:8 439> &$$ U4 43 %'Q%? S!1%'2 4U ,$ 8U 4%3> S!1%'2 4U4 $ Aspergillus sps $,$)1 $ $ 49$$ #$ S!%'2 4> 4 92 4U4 3$ )1! 49$$ $$ 67 Name Guide Project S 43 8 S!1& 4:U !'Q%@$ N$/N30 3$ 43 8 S)1& 4:U !'Q%@$ N$/N30 23 43 N$ )1! 4U+ 4U 9 43 8$&24F S)1&24F 44 & S 43 8$&24F S)1&24F 44 & S 4%3> JRF-DBT 4 S 49$$ 83$ )1%'2 4> 3 48+3 ,$ )1! 49$$ $M< $ 33+> 4U &$ JRF-DBT 43 $ 4U4 3 48+3 +%$$ )1%'2 4 $ G. Gowthaman 43 )$3 JRF-DBT 4U %@ $$

N 4U4 3\W )1! 4%3> " $ S) 4 #3% 3>1! S%3 4%3> $ )1# AspergillusFusarium$ corneal ulcer

68